Codexis, Inc.
CDXSCodexis, Inc. in brief
Codexis, Inc. is a listed company in the Biotechnology industry, based in Redwood City, California, USA. It was founded in 2002. Its market value was $140 M on 26 October 2026, which makes it the 17,521st largest listed company in the world and the 3,338th largest in the USA on this site. In the year to December 2025 it had sales of $70 M and a net loss of $44 M. It employs about 261 people and Alison Moore is its chief executive. Its largest product and service lines by sales in 2025 were Research and development revenue (63%). By market, the largest shares of its 2025 sales came from Americas (62%), USA (62%) and APAC (25%). Its shares trade under the symbol CDXS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Codexis, Inc.
Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Codexis, Inc. timeline
- 2002
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- 🔔· approximateInitial public offering on Nasdaq as CDXS
- 2015
- •Legal Entity Identifier issuedLEI 549300KGLM6CDPTVSE20 registered.
- 2022
- 💰Record revenue of $139 millionFY2022, the highest of the 8 years on record.
Events of Codexis, Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,994 (Jan 2020) · #1,916 (Jan 2021) · #2,032 (Jan 2022) · #3,268 (Dec 2022) · #3,420 (Jul 2023) · #3,234 (Jan 2024) · #1,915 (Mar 2026) · #3,176 (Aug 2026) · #3,298 (Oct 2026) · #3,342 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.6×
- Price / book
- 2.8×
- Free cash flow yield
- -17.0%
- Net margin (TTM)
- -21.8%
- Operating margin
- -59.3%
- Return on equity
- -38.0%
- Liabilities / assets
- 65.8%
- Net debt
- $-11M
- Revenue growth
- +18.6%
- R&D / revenue
- 74.3%
- Revenue per employee
- $270 K
- Profit per employee
- $-168 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $70M | +18.6% | $-42M | $-44M | -62.5% |
| Dec 2024 | $59M | -15.4% | $-59M | $-65M | -110.0% |
| Dec 2023 | $70M | -49.4% | $-68M | $-76M | -108.7% |
| Dec 2022 | $139M | +32.3% | $-35M | $-34M | -24.2% |
| Dec 2021 | $105M | +51.7% | $-23M | $-21M | -20.3% |
| Dec 2020 | $69M | +0.9% | $-24M | $-24M | -34.8% |
| Dec 2019 | $68M | +13.0% | $-13M | $-12M | -17.4% |
| Dec 2018 | $61M | — | $-11M | $-11M | -18.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-19M | $4M | $-24M | $-0.50 | — |
| Dec 2024 | $-49M | $4M | $-54M | $-0.89 | — |
| Dec 2023 | $-53M | $4M | $-57M | $-1.12 | — |
| Dec 2022 | $11M | $8M | $3M | $-0.51 | — |
| Dec 2021 | $-14M | $14M | $-28M | $-0.33 | — |
| Dec 2020 | $-16M | $4M | $-20M | $-0.40 | — |
| Dec 2019 | $-13M | $4M | $-16M | $-0.21 | — |
| Dec 2018 | $-14M | $3M | $-17M | $-0.21 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $19M (+124.0% on a year earlier), net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 10, 20268-KCurrent reportMaterial agreement · Agreement ended · New financial obligation · Unregistered share sale
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 27, 20268-KCurrent reportOther events
- Jul 23, 20268-KCurrent reportResults of operations · Other events
- Jun 22, 20268-KCurrent reportShareholder vote
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Apr 28, 2026DEF 14AProxy statement
- Apr 14, 20268-KCurrent reportDirectors or officers changed
Official filings of Codexis, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $70 M
- Operating income
- $-42 M
- Net income
- $-44 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $148 M
- Total liabilities
- $97 M
- Total equity
- $51 M
As of December-2025
Top 100 institutional investors in Codexis, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Aberdeen Group plc | 10,797,702 | +4,027,748 (+59.49%) | 9.85% | $15 M | Nov 10, 2026 |
| 2 | BlackRock, Inc. | 8,314,154 | +1,029,802 (+14.14%) | 7.59% | $12 M | Nov 13, 2026 |
| 3 | Telemark Asset Management, LLC | 7,846,411 | +4,000,000 (+103.99%) | 7.16% | $11 M | Nov 10, 2026 |
| 4 | Millennium Management LLC | 4,769,627 | -779,512 (-14.05%) | 4.35% | $7 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 4,344,228 | +727,119 (+20.10%) | 3.96% | $6 M | Nov 13, 2026 |
| 6 | Ameriprise Financial Inc | 3,055,267 | -754,173 (-19.80%) | 2.79% | $4 M | Nov 16, 2026 |
| 7 | Nantahala Capital Management, LLC | 2,597,869 | -4,649,357 (-64.15%) | 2.37% | $4 M | Nov 13, 2026 |
| 8 | Opaleye Management Inc. | 2,590,000 | -4,195,000 (-61.83%) | 2.36% | $4 M | Nov 16, 2026 |
| 9 | Geode Capital Management, LLC | 2,472,631 | +310,238 (+14.35%) | 2.26% | $3 M | Nov 6, 2026 |
| 10 | D. E. Shaw & Co., Inc. | 1,786,025 | +444,011 (+33.09%) | 1.63% | $2 M | Nov 16, 2026 |
| 11 | State Street Corp | 1,635,386 | -121,428 (-6.91%) | 1.49% | $2 M | Nov 12, 2026 |
| 12 | Jacobs Levy Equity Management, Inc | 1,543,312 | +213,107 (+16.02%) | 1.41% | $2 M | Nov 16, 2026 |
| 13 | Vanguard Portfolio Management LLC | 1,425,324 | +118,153 (+9.04%) | 1.30% | $2 M | Nov 13, 2026 |
| 14 | Private Advisor Group, LLC | 1,206,163 | New | 1.10% | $2 M | Nov 10, 2026 |
| 15 | Acadian Asset Management LLC | 1,113,604 | +755,319 (+210.82%) | 1.02% | $2 M | Nov 9, 2026 |
| 16 | Perkins Capital Management Inc | 1,021,850 | +495,750 (+94.23%) | 0.93% | $1 M | Nov 2, 2026 |
| 17 | Two Sigma Investments, LP | 972,865 | +276,266 (+39.66%) | 0.89% | $1 M | Nov 16, 2026 |
| 18 | Goldman Sachs Group Inc | 840,866 | +405,942 (+93.34%) | 0.77% | $1 M | Nov 16, 2026 |
| 19 | Northern Trust Corp | 822,353 | +139,413 (+20.41%) | 0.75% | $1 M | Nov 16, 2026 |
| 20 | Man Group plc | 786,317 | +220,724 (+39.03%) | 0.72% | $1 M | Nov 16, 2026 |
| 21 | AQR Capital Management LLC | 769,535 | -75,896 (-8.98%) | 0.70% | $1 M | Nov 16, 2026 |
| 22 | Morgan Stanley | 767,943 | +118,773 (+18.30%) | 0.70% | $1 M | Nov 13, 2026 |
| 23 | Franklin Templeton Inc | 732,767 | +54,127 (+7.98%) | 0.67% | $1 M | Nov 12, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 712,294 | +131,236 (+22.59%) | 0.65% | $1 M | Nov 13, 2026 |
| 25 | Stonepine Capital Management, LLC | 676,973 | +567,311 (+517.33%) | 0.62% | $1 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Post Resch Tallon Group Inc. | 573,953 | +10,475 (+1.86%) | 0.52% | $1 M | Oct 9, 2026 |
| 27 | Arrowstreet Capital, Limited Partnership | 536,983 | +388,932 (+262.70%) | 0.49% | $1 M | Nov 13, 2026 |
| 28 | Los Angeles Capital Management LLC | 490,937 | +442,812 (+920.13%) | 0.45% | $1 M | Nov 12, 2026 |
| 29 | FMR LLC | 486,907 | +8,424 (+1.76%) | 0.44% | $1 M | Nov 10, 2026 |
| 30 | Bank Of America Corp /de/ | 474,079 | +233,562 (+97.11%) | 0.43% | $1 M | Nov 16, 2026 |
| 31 | Gsa Capital Partners LLP | 467,138 | +425,327 (+1017.26%) | 0.43% | $1 M | Nov 16, 2026 |
| 32 | Assenagon Asset Management S.A. | 463,055 | -2,093,357 (-81.89%) | 0.42% | $1 M | Oct 15, 2026 |
| 33 | Citadel Advisors LLC | 451,630 | +260,050 (+135.74%) | 0.41% | $1 M | Nov 16, 2026 |
| 34 | XTX Topco Ltd | 438,691 | +198,064 (+82.31%) | 0.40% | $1 M | Nov 16, 2026 |
| 35 | Price T Rowe Associates Inc /MD/ | 421,336 | +354,412 (+529.57%) | 0.38% | $1 M | Nov 16, 2026 |
| 36 | Royal Bank Of Canada | 403,131 | +140,205 (+53.32%) | 0.37% | $1 M | Nov 16, 2026 |
| 37 | Prescott Group Capital Management, L.L.C. | 400,000 | New | 0.36% | $1 M | Oct 30, 2026 |
| 38 | UBS Group AG | 359,427 | +119,520 (+49.82%) | 0.33% | $0 M | Nov 10, 2026 |
| 39 | Tudor Investment Corp Et Al | 357,925 | 0 (0.00%) | 0.33% | $0 M | Nov 16, 2026 |
| 40 | Nuveen, LLC | 314,618 | -77,649 (-19.79%) | 0.29% | $0 M | Nov 10, 2026 |
| 41 | Potomac Capital Management, Inc. | 310,000 | +50,000 (+19.23%) | 0.28% | $0 M | Nov 13, 2026 |
| 42 | Russell Investments Group, Ltd. | 308,332 | +237 (+0.08%) | 0.28% | $0 M | Nov 6, 2026 |
| 43 | Charles Schwab Investment Management Inc | 296,325 | +54,114 (+22.34%) | 0.27% | $0 M | Nov 16, 2026 |
| 44 | Graham Capital Management, L.P. | 277,230 | +265,156 (+2196.09%) | 0.25% | $0 M | Nov 16, 2026 |
| 45 | Bank of New York Mellon Corp | 250,632 | +24,593 (+10.88%) | 0.23% | $0 M | Nov 5, 2026 |
| 46 | Algert Global LLC | 218,050 | -212,860 (-49.40%) | 0.20% | $0 M | Nov 17, 2026 |
| 47 | Dimensional Fund Advisors LP | 201,464 | -111,922 (-35.71%) | 0.18% | $0 M | Nov 4, 2026 |
| 48 | Invesco Ltd. | 198,321 | +36,050 (+22.22%) | 0.18% | $0 M | Nov 12, 2026 |
| 49 | Barclays PLC | 187,238 | +31,964 (+20.59%) | 0.17% | $0 M | Nov 6, 2026 |
| 50 | Strs Ohio | 169,800 | +48,800 (+40.33%) | 0.15% | $0 M | Oct 30, 2026 |
| 51 | Squarepoint Ops LLC | 160,028 | New | 0.15% | $0 M | Nov 9, 2026 |
| 52 | Prudential Financial Inc | 156,175 | +129,795 (+492.02%) | 0.14% | $0 M | Nov 16, 2026 |
| 53 | Renaissance Technologies LLC | 130,935 | +89,435 (+215.51%) | 0.12% | $0 M | Nov 12, 2026 |
| 54 | Alliancebernstein L.P. | 126,430 | 0 (0.00%) | 0.12% | $0 M | Nov 16, 2026 |
| 55 | Panagora Asset Management Inc | 124,551 | +66,351 (+114.01%) | 0.11% | $0 M | Nov 12, 2026 |
| 56 | Bridgeway Capital Management, LLC | 123,980 | -1,928 (-1.53%) | 0.11% | $0 M | Nov 16, 2026 |
| 57 | Canada Pension Plan Investment Board | 120,100 | New | 0.11% | $0 M | Nov 16, 2026 |
| 58 | Empowered Funds, LLC | 115,072 | New | 0.10% | $0 M | Nov 13, 2026 |
| 59 | Rhumbline Advisers | 98,249 | -5,052 (-4.89%) | 0.09% | $0 M | Nov 10, 2026 |
| 60 | Deutsche Bank AG\ | 84,357 | -11,872 (-12.34%) | 0.08% | $0 M | Nov 6, 2026 |
| 61 | Citigroup Inc | 77,471 | +34,138 (+78.78%) | 0.07% | $0 M | Nov 4, 2026 |
| 62 | LPL Financial LLC | 76,563 | +3 (0.00%) | 0.07% | $0 M | Nov 6, 2026 |
| 63 | Quadrature Capital Ltd | 68,385 | +58,204 (+571.69%) | 0.06% | $0 M | Nov 13, 2026 |
| 64 | Point72 Asset Management, L.P. | 65,969 | New | 0.06% | $0 M | Nov 16, 2026 |
| 65 | Envestnet Asset Management Inc | 63,087 | +11,712 (+22.80%) | 0.06% | $0 M | Nov 16, 2026 |
| 66 | Marshall Wace, LLP | 55,246 | -61,889 (-52.84%) | 0.05% | $0 M | Nov 13, 2026 |
| 67 | Jpmorgan Chase & Co | 54,622 | +12,761 (+30.48%) | 0.05% | $0 M | Nov 12, 2026 |
| 68 | Wells Fargo & Company/mn | 53,489 | -48,437 (-47.52%) | 0.05% | $0 M | Nov 16, 2026 |
| 69 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 48,942 | +9,138 (+22.96%) | 0.04% | $0 M | Nov 16, 2026 |
| 70 | BNP Paribas Financial Markets | 39,623 | +24,162 (+156.28%) | 0.04% | $0 M | Nov 12, 2026 |
| 71 | Osaic Holdings, Inc. | 36,366 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 72 | Commonwealth Equity Services, LLC | 36,179 | -25 (-0.07%) | 0.03% | $0 M | Nov 2, 2026 |
| 73 | Vanguard Global Advisers, LLC | 33,134 | +532 (+1.63%) | 0.03% | $0 M | Nov 13, 2026 |
| 74 | Bank Of Montreal /can/ | 31,661 | -3,337 (-9.53%) | 0.03% | $0 M | Nov 9, 2026 |
| 75 | Krilogy Financial LLC | 30,141 | -4,684 (-13.45%) | 0.03% | $0 M | Oct 13, 2026 |
| 76 | Aigen Investment Management, LP | 29,263 | New | 0.03% | $0 M | Nov 16, 2026 |
| 77 | Evergreen Capital Management LLC | 29,000 | 0 (0.00%) | 0.03% | $0 M | Oct 23, 2026 |
| 78 | Capital Advisors, Ltd. LLC | 28,890 | 0 (0.00%) | 0.03% | $0 M | Oct 27, 2026 |
| 79 | Dynamic Technology Lab Private Ltd | 28,071 | -4,929 (-14.94%) | 0.03% | $0 M | Nov 13, 2026 |
| 80 | Guggenheim Capital LLC | 26,391 | +233 (+0.89%) | 0.02% | $0 M | Nov 16, 2026 |
| 81 | Axq Capital, LP | 24,863 | New | 0.02% | $0 M | Nov 12, 2026 |
| 82 | Susquehanna International Group, LLP | 23,543 | -58,980 (-71.47%) | 0.02% | $0 M | Nov 16, 2026 |
| 83 | Two Sigma Securities, LLC | 20,465 | New | 0.02% | $0 M | Nov 16, 2026 |
| 84 | Blair William & Co/il | 20,000 | -10,219 (-33.82%) | 0.02% | $0 M | Nov 10, 2026 |
| 85 | China Universal Asset Management Co., Ltd. | 19,981 | +5,515 (+38.12%) | 0.02% | $0 M | Oct 28, 2026 |
| 86 | Police & Firemen's Retirement System of New Jersey | 19,441 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 87 | Voya Investment Management LLC | 18,561 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 88 | Vanguard Personalized Indexing Management, LLC | 17,862 | -86 (-0.48%) | 0.02% | $0 M | Nov 16, 2026 |
| 89 | Tower Research Capital LLC (TRC) | 17,648 | +5,593 (+46.40%) | 0.02% | $0 M | Nov 16, 2026 |
| 90 | Allspring Global Investments Holdings, LLC | 17,066 | +5,856 (+52.24%) | 0.02% | $0 M | Nov 4, 2026 |
| 91 | New York State Common Retirement Fund | 16,888 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 92 | StoneX Group Inc. | 16,859 | New | 0.02% | $0 M | Nov 3, 2026 |
| 93 | ProShare Advisors LLC | 16,636 | +2,333 (+16.31%) | 0.02% | $0 M | Oct 29, 2026 |
| 94 | Engineers Gate Manager LP | 16,517 | New | 0.02% | $0 M | Nov 16, 2026 |
| 95 | Navalign, LLC | 15,340 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 96 | Elmwood Wealth Management, Inc. | 12,695 | 0 (0.00%) | 0.01% | $0 M | Oct 14, 2026 |
| 97 | CIBC Bancorp USA Inc. | 11,911 | New | 0.01% | $0 M | Nov 13, 2026 |
| 98 | Victory Capital Management Inc | 11,595 | New | 0.01% | $0 M | Nov 10, 2026 |
| 99 | Simplicity Wealth,LLC | 10,980 | -6,458 (-37.03%) | 0.01% | $0 M | Oct 23, 2026 |
| 100 | GAMCO Investors, Inc. Et Al | 10,000 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
Mutual funds holding Codexis, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 4.44 M | $10 M | 4.0% | 0.74% | −21% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.63 M | $6 M | 2.4% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 2.34 M | $5 M | 2.1% | 0.77% | −24% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.29 M | $5 M | 2.1% | <0.01% | +3.0% | Jun 30, 2026 |
| 🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC | 2.66 M | $4 M | 2.4% | 0.15% | +6.4% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 895,869 | $2 M | 0.82% | <0.01% | +1.7% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 696,097 | $2 M | 0.64% | 0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 Putnam Small Cap Value FundPutnam Investment Management, LLC | 492,703 | $1 M | 0.45% | 0.46% | −6.9% | May 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 593,659 | $1 M | 0.54% | 0.01% | −13% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 942,511 | $1 M | 0.86% | <0.01% | +6.7% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 458,168 | $1 M | 0.42% | <0.01% | +4.1% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 418,879 | $1 M | 0.38% | <0.01% | −0.1% | May 31, 2026 |
| 🇺🇸 Columbia Variable Portfolio - Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC | 481,660 | $1 M | 0.44% | 0.24% | −3.4% | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 398,987 | $1 M | 0.36% | 0.05% | +239% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 290,804 | $1 M | 0.27% | 0.04% | +31% | Jun 30, 2026 |
| 🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC | 213,439 | $0 M | 0.19% | 0.03% | +5.9% | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 316,606 | $0 M | 0.29% | <0.01% | +33% | Jul 31, 2026 |
| 🇺🇸 Putnam VT Small Cap Value FundPutnam Investment Management, LLC | 185,697 | $0 M | 0.17% | 0.34% | −4.9% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 147,202 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 148,756 | $0 M | 0.14% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 120,049 | $0 M | 0.11% | <0.01% | +4.4% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 137,295 | $0 M | 0.13% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 130,110 | $0 M | 0.12% | <0.01% | +3.1% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 196,089 | $0 M | 0.18% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 117,000 | $0 M | 0.11% | 0.18% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 183,067 | $0 M | 0.17% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 107,077 | $0 M | 0.10% | <0.01% | +128% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 92,542 | $0 M | 0.08% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 69,191 | $0 M | 0.06% | 0.01% | +1.2% | May 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 76,850 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 74,090 | $0 M | 0.07% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 69,284 | $0 M | 0.06% | 0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 105,313 | $0 M | 0.10% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 52,039 | $0 M | 0.05% | <0.01% | −31% | May 31, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 98,404 | $0 M | 0.09% | 0.05% | +49% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 59,000 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 50,641 | $0 M | 0.05% | 0.01% | +9.7% | Jun 30, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 40,867 | $0 M | 0.04% | <0.01% | −78% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 46,017 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 71,447 | $0 M | 0.07% | <0.01% | −9.7% | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 41,453 | $0 M | 0.04% | <0.01% | −62% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 40,840 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 32,365 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 37,998 | $0 M | 0.03% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 AVIP Fidelity Institutional AM Equity Growth PortfolioCONSTELLATION INVESTMENTS INC | 37,883 | $0 M | 0.03% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 28,868 | $0 M | 0.03% | <0.01% | new | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 56,705 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 33,021 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 52,788 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 30,376 | $0 M | 0.03% | <0.01% | +59% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 29,493 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc. | 28,992 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 28,795 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 23,200 | $0 M | 0.02% | <0.01% | +12% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 45,863 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 45,287 | $0 M | 0.04% | <0.01% | +25% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 27,054 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 41,308 | $0 M | 0.04% | <0.01% | +6.7% | Jul 31, 2026 |
| 🇺🇸 Guardian Large Cap Fundamental Growth VIP FundPark Avenue Institutional Advisers LLC | 22,776 | $0 M | 0.02% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 19,664 | $0 M | 0.02% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 19,596 | $0 M | 0.02% | <0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 19,608 | $0 M | 0.02% | 0.02% | +19% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 18,093 | $0 M | 0.02% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 17,822 | $0 M | 0.02% | <0.01% | −16% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 17,616 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 28,166 | $0 M | 0.03% | <0.01% | −0.8% | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 13,961 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 16,710 | $0 M | 0.02% | <0.01% | −0.7% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 12,306 | $0 M | 0.01% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 13,414 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 12,386 | $0 M | 0.01% | <0.01% | −1.0% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 19,277 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 11,874 | $0 M | 0.01% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 11,736 | $0 M | 0.01% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 10,779 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 16,975 | $0 M | 0.02% | <0.01% | −18% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 9,953 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 9,620 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 8,880 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 8,530 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 8,428 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 6,744 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 13,274 | $0 M | 0.01% | <0.01% | +8.0% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 8,037 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 12,035 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 6,781 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 6,687 | $0 M | <0.01% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 6,196 | $0 M | <0.01% | <0.01% | −2.4% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 9,973 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 9,730 | $0 M | <0.01% | <0.01% | −3.5% | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 5,744 | $0 M | <0.01% | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 5,551 | $0 M | <0.01% | <0.01% | −1.6% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 4,198 | $0 M | <0.01% | <0.01% | +8.7% | May 31, 2026 |
| 🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC | 5,038 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 6,619 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 3,320 | $0 M | <0.01% | <0.01% | −39% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 3,283 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 6,396 | $0 M | <0.01% | <0.01% | +30% | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 3,667 | $0 M | <0.01% | <0.01% | −53% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 3,534 | $0 M | <0.01% | <0.01% | −18% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Codexis, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Alison MoorePresident and CEO, Director | Sell | -10,651 | $1.137 | $12 K | 233,520 | Form 4 |
| filed | Raymond De VreDirector | Sell | -1,088 | $1.110 | $1 K | 83,723 | Form 4 |
| filed | Alison MoorePresident and CEO, Director | Sell | -6,335 | $1.361 | $9 K | 244,171 | Form 4 |
| filed | Georgia ErbezSee Remarks | Sell | -6,335 | $1.361 | — | 60,475 | Form 4 |
| filed | Raymond De VreDirector | Sell | -2,605 | $2.370 | $6 K | 84,811 | Form 4 |
| filed | Stefan LutzChief Scientific Officer | Sell | -5,862 | $1.130 | $7 K | 130,421 | Form 4 |
| filed | Georgia ErbezSee Remarks | Sell | -3,826 | $1.310 | — | 66,810 | Form 4 |
| filed | Alison MoorePresident and CEO, Director | Sell | -3,826 | $1.310 | $5 K | 250,506 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Codexis, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 4,365 shares at $1.28
- : 2,689 shares at $1.32
- : 268 shares at $1.48
- : 3,815 shares at $1.45
- : 1,335 shares at $1.40
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Codexis, Inc. scorecard#
Passes 7 of the 22 checks that could be worked out: strongest in financial health (3 of 5), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.8×Price to book 2.8× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-17.0%Free cash flow is -17.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✓Revenue grew in the newest year18.6%Revenue up 18.6% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-20.2%-20.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-20.2%-20.2% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.50 vs -0.89Diluted EPS -0.50 in fiscal 2025 against -0.89 the year before (report's currency).
- ✗Net income higher than five years earlier-$44 M-$44 M in fiscal 2025 against -$24 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$44 MNet income -$44 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-59.3%-59.3% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-74.9%-74.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-59.3%-59.3% in fiscal 2025 against -25.2% in 2022.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities3.8×Current ratio 3.82 at the end of fiscal 2025.
- ✓Debt below equity0.8×Debt to equity 0.79 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $11 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-4.76Z-score -4.76 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year18.7%Diluted shares up 18.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Codexis, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -59.3% | -60.5% | |
| Net margin | -62.5% | -68.9% | |
| Return on equity | -74.9% | -61.0% | |
| Revenue growth, 3 years a year | -20.2% | 12.9% | |
| Revenue growth | 18.6% | 15.8% | |
| Debt to equity | 0.79× | 0.26× |
4of 9on the Piotroski tests of financial strength
- Net loss of $44 million, the 17th loss-making year in a row.
- Free cash flow was negative: -$24 million.
- The share count rose 18.7% in the year.
- More cash than debt: net cash of $11 million.
Codexis, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 70+18.6%100% | 59−15.4%100% | 70−49.4%100% | 139+32.3%100% | 105+51.7%100% | 69+0.9%100% | 68+13.0%100% | 61+21.1%100% | 50+2.4%100% | 49—100% | |
| Cost of revenue | 9.3−42.7%13.3% | 16+27.2%27.4% | 13−66.3%18.3% | 38+71.3%27.4% | 22+61.6%21.2% | 14−12.1%19.9% | 16+23.9%22.8% | 13−11.9%20.8% | 14+46.9%28.6% | 9.8—20.0% | |
| Research and development | 52+13.1%74.3% | 46−21.4%78.0% | 59−26.5%83.9% | 80+43.2%57.8% | 56+26.6%53.4% | 44+30.4%64.0% | 34+13.0%49.5% | 30+1.1%49.5% | 30+33.4%59.3% | 22—45.5% | |
| Selling, general and administrative | 47−14.6%66.9% | 55+3.6%92.9% | 53+2.1%75.9% | 52+5.8%37.6% | 49+40.7%47.1% | 35+11.3%50.8% | 32+7.5%46.0% | 29+1.0%48.3% | 29+14.1%58.0% | 25—52.0% | |
| Operating expenses | — | — | — | — | — | — | — | 72−1.5%119% | 73+27.2%146% | 57—118% | |
| Total costs and expenses | 112−4.9%159% | 118−14.7%199% | 138−20.3%197% | 173+36.1%125% | 127+37.1%122% | 93+14.8%135% | 81+12.7%118% | 72−1.5%119% | 73+27.2%146% | 57—118% | |
| Operating income | −42—−59.3% | −59—−98.6% | −68—−97.0% | −35—−25.2% | −23—−21.7% | −24—−34.6% | −13—−18.3% | −11—−18.6% | −23—−45.9% | −8.6—−17.5% | |
| Interest and finance income | 2.6−28.5%3.7% | 3.7−12.0%6.2% | 4.2+190%5.9% | 1.4+214%1.0% | 0.5+13.3%0.4% | 0.4−68.5%0.6% | 1.3+91.8%1.9% | 0.7+356%1.1% | 0.1+145%0.3% | 0.1—0.1% | |
| Provision for credit losses | — | — | 0−100%0.0% | 0.1−84.2%0.0% | 0.3+755%0.3% | 0.0—0.1% | 0—0.0% | — | — | — | |
| Other non-operating income (expense) | −4.8—−6.8% | −10—−17.5% | −12−9998%−17.5% | 0.1−89.2%0.1% | 1.1—1.1% | −0.2—−0.2% | −0.7—−1.0% | −0.3—−0.5% | −0.1—−0.2% | −0.1—−0.2% | |
| Income before tax | −44—−62.4% | −65—−110% | −76—−109% | −33—−24.0% | −21—−20.1% | −24—−34.3% | −12—−17.4% | −11—−18.0% | −23—−45.8% | −8.6—−17.6% | |
| Income tax | 0.0+38.2%0.1% | 0.0−50.7%0.1% | 0.1−75.0%0.1% | 0.3+46.0%0.2% | 0.2−44.2%0.2% | 0.3+1894%0.5% | 0.0—0.0% | −0.0−146%−0.1% | 0.1—0.2% | −0.0—−0.1% | |
| Net income attributable to shareholders | −44—−62.5% | −65—−110% | −76—−109% | −34—−24.2% | −21—−20.3% | −24—−34.8% | −12—−17.4% | −11—−18.0% | −23—−46.0% | −8.6—−17.5% | |
| Earnings per share, basic | -0.50—— | -0.89—— | -1.12—— | -0.51—— | -0.33—— | -0.40—— | -0.21—— | -0.21—— | -0.50—— | -0.21—— | |
| Earnings per share, diluted | -0.50—— | -0.89—— | -1.12—— | -0.51—— | -0.33—— | -0.40—— | -0.21—— | -0.21—— | -0.50—— | -0.21—— | |
| Shares, weighted average (basic) | 87+18.7%— | 73+7.7%— | 68+4.3%— | 65+1.2%— | 65+8.8%— | 59+5.0%— | 57—— | — | — | — | |
| Shares, weighted average (diluted) | 87+18.7%— | 73+7.7%— | 68+4.3%— | 65+1.2%— | 65+8.8%— | 59+5.0%— | 57+8.3%— | 52+12.9%— | 46+13.8%— | 41—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 51+164%34.4% | 19−70.4%12.9% | 65r65−42.9%47.7% | 114−2.4%45.5% | 117−21.7%47.4% | 149+64.8%67.3% | 90+70.6%60.7% | 53+69.9%66.9% | 31+62.3%58.2% | 19—54.0% | |
| Short-term investments | 27−49.4%18.5% | 54—36.4% | 0—0.0% | — | — | — | — | — | — | — | |
| Receivables | 11−43.4%7.2% | 19+88.2%12.7% | 10−68.5%7.3% | 32r32+27.9%12.7% | 25r25+79.6%10.1% | 14r14+53.3%6.3% | 9.1r9.0−21.5%6.1% | 12+0.9%14.6% | 11r12+93.2%21.3% | 5.9—16.6% | |
| Inventory | 1.8+1.0%1.2% | 1.8−33.0%1.2% | 2.7+32.3%2.0% | 2.0+74.9%0.8% | 1.2+20.3%0.5% | 1.0+160%0.4% | 0.4−37.0%0.2% | 0.6−43.1%0.7% | 1.0+25.6%1.9% | 0.8—2.3% | |
| Other current assets | 0.50.0%0.3% | 0.5−16.7%0.3% | 0.6−14.3%0.4% | 0.7r5.5−87.7%0.3% | 5.7+66.9%2.3% | 3.4+35.6%1.5% | 2.5+136%1.7% | 1.1+8.5%1.3% | 1.0−20.5%1.8% | 1.2—3.5% | |
| Current assets | 97−2.0%65.5% | 99+5.7%66.3% | 93−42.6%68.4% | 163+0.6%65.1% | 162−12.2%65.7% | 184+61.5%83.2% | 114+67.5%76.6% | 68+51.4%86.0% | 45+65.4%84.0% | 27—76.4% | |
| Property, plant and equipment | 13−8.3%8.8% | 14−8.3%9.5% | 15−31.5%11.3% | 23+5.9%9.0% | 21+121%8.7% | 9.7+54.0%4.4% | 6.3+32.0%4.2% | 4.8+69.1%6.0% | 2.8+30.6%5.2% | 2.2—6.0% | |
| Right-of-use (leased) assets | 31+6.3%20.6% | 29+118%19.3% | 13−66.5%9.6% | 39−11.0%15.7% | 44+106%17.9% | 21−10.3%9.6% | 24—16.0% | 0—0.0% | — | — | |
| Goodwill | 2.50.0%1.7% | 2.50.0%1.7% | 2.5−24.0%1.8% | 3.20.0%1.3% | 3.20.0%1.3% | 3.20.0%1.5% | 3.20.0%2.2% | 3.20.0%4.1% | 3.20.0%6.0% | 3.2—9.1% | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Total assets | 148−0.8%100% | 149+9.1%100% | 137−45.5%100% | 250+1.6%100% | 246+11.2%100% | 222+48.7%100% | 149+88.0%100% | 79+47.8%100% | 54+50.4%100% | 36—100% | |
| Accounts payable | 1.6−45.2%1.1% | 2.8−52.3%1.9% | 5.9+83.2%4.4% | 3.2+8.4%1.3% | 3.0+0.8%1.2% | 3.0+13.3%1.3% | 2.6−14.1%1.8% | 3.1−14.0%3.8% | 3.5−16.2%6.6% | 4.2—11.9% | |
| Debt due within a year | 0—0.0% | — | — | — | — | — | — | — | — | — | |
| Current liabilities | 25+7.1%17.1% | 24−34.0%15.9% | 36−27.0%26.2% | 49+47.0%19.6% | 33+33.6%13.5% | 25+62.3%11.3% | 15−15.0%10.3% | 18−27.4%22.8% | 25+102%46.5% | 12—34.7% | |
| Long-term debt | 40+38.7%27.1% | 29—19.4% | 0—0.0% | — | — | — | — | — | 0.3—0.6% | 0—0.0% | |
| Lease liabilities (non-current) | 30+7.1%20.4% | 28+130%18.9% | 12−68.0%9.0% | 38−12.1%15.3% | 44+95.1%17.7% | 22−10.5%10.1% | 25—16.7% | 0—0.0% | — | — | |
| Total liabilities | 97+18.5%65.8% | 82+64.3%55.1% | 50−52.7%36.6% | 106+28.8%42.2% | 82+59.1%33.3% | 52+18.3%23.3% | 44+89.6%29.2% | 23−21.0%29.0% | 29+75.7%54.2% | 17—46.4% | |
| Retained earnings | −607—−411% | −563—−378% | −498—−364% | −421—−168% | −388—−157% | −366—−165% | −342—−230% | −330—−417% | −315—−588% | −292—−819% | |
| Shareholders' equity | 51−24.5%34.2% | 67−22.7%44.9% | 87−40.2%63.4% | 145−11.9%57.8% | 164−3.4%66.7% | 170+61.2%76.7% | 106+87.4%70.8% | 56+129%71.0% | 25+28.5%45.8% | 19—53.6% | |
| Total liabilities and equity | 148−0.8%100% | 149+9.1%100% | 137−45.5%100% | 250+1.6%100% | 246+11.2%100% | 222+48.7%100% | 149+88.0%100% | 79+47.8%100% | 54+50.4%100% | 36—100% | |
| Shares outstanding | 90+10.5%— | 82+17.1%— | 70+6.2%— | 66+1.1%— | 65+1.3%— | 64+9.2%— | 59+8.9%— | 54r55+11.8%— | 48+17.2%— | 41—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 5.2+6.1%7.5% | 4.9−10.4%8.3% | 5.5+2.1%7.9% | 5.4—3.9% | — | — | — | — | — | — | |
| Share-based compensation | 9.6−26.5%13.7% | 13+31.3%22.1% | 10.0−31.4%14.2% | 15+25.3%10.5% | 12+50.0%11.1% | 7.7+11.3%11.2% | 6.9−12.0%10.1% | 7.9+11.3%13.0% | 7.1+25.0%14.2% | 5.7—11.6% | |
| Cash from operating activities | −19—−27.5% | −49—−83.3% | −53−566%−75.0% | 11—8.1% | −14—−13.6% | −16—−23.8% | −13—−18.3% | −14—−23.3% | −8.8r−8.8—−17.5% | −1.9r−2.7—−3.8% | |
| Capital expenditure | −4.5—−6.4% | −4.3—−7.3% | −4.4—−6.3% | −8.3—−6.0% | −14—−13.2% | −3.7—−5.4% | −3.7—−5.4% | −2.8—−4.6% | −1.0—−2.0% | −0.9—−1.8% | |
| Cash from investing activities | 24—33.4% | −57—−96.0% | −4.9—−6.9% | −14—−9.8% | −21—−20.4% | −5.7—−8.3% | −3.7—−5.4% | −2.8—−4.6% | −1.0r−0.9—−2.0% | −0.8r−0.8—−1.7% | |
| Debt issued | 9.9−66.5%14.1% | 30—49.7% | 0—0.0% | 0—0.0% | — | — | — | — | — | — | |
| Shares issued | 17−44.9%24.5% | 31+262%52.8% | 8.7—12.3% | 0—0.0% | 0−100%0.0% | 86—125% | 0r50−100%0.0% | 37+57.7%61.9% | 24—47.5% | 0—0.0% | |
| Cash from financing activities | 28−53.9%39.7% | 61+641%102% | 8.2—11.6% | −0.6−115%−0.4% | 3.8−95.3%3.6% | 81+49.8%117% | 54+39.9%78.8% | 39+78.1%63.7% | 22—43.3% | −0.5—−1.0% | |
| Change in cash | 32—45.5% | −46—−77.3% | −49—−70.3% | −2.9—−2.1% | −32−154%−30.5% | 59+55.3%84.9% | 38+73.8%55.1% | 22+82.2%35.8% | 12r12—23.8% | −3.2r−4.0—−6.5% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 88+66.9%100% | 19+124%100% | 15−2.7%100% | 15+102%100% | 39*+81.3%100% | 8.6−33.0%100% | 15+92.1%100% | 7.5−55.8%100% | 21*−19.2%100% | 13—100% | 8.0—100% | 17—100% | 27*—100% | |
| Cost of revenue | 12+6.2%13.2% | 4.0+62.8%20.8% | 3.5+67.4%23.5% | 2.1−24.5%13.5% | 2.0*−44.1%5.2% | 2.5−42.9%28.7% | 2.1−39.4%13.7% | 2.7−43.7%36.2% | 3.7*+27.7%17.0% | 4.3—33.6% | 3.5—43.4% | 4.9—28.4% | 2.9*—10.8% | |
| Research and development | 47−9.9%53.7% | 13−9.2%65.3% | 12−15.0%78.5% | 11−11.5%75.1% | 12*−3.1%30.1% | 14+20.5%161% | 14+20.7%89.9% | 13+15.1%172% | 12*+7.7%56.4% | 12—89.7% | 11—143% | 11—65.9% | 11*—42.3% | |
| Selling, general and administrative | 42−14.2%47.5% | 10−10.0%52.4% | 11−11.3%73.3% | 9.8−20.8%64.1% | 11*−14.3%28.7% | 11−17.3%130% | 12−21.4%80.4% | 12−3.9%164% | 13*+7.1%60.8% | 14—106% | 16—196% | 13—75.3% | 12*—45.9% | |
| Total costs and expenses | 104−7.2%118% | 27−3.1%139% | 26−7.3%175% | 23−16.9%153% | 28*−1.5%72.9% | 28−6.3%320% | 28−8.2%184% | 28−3.2%372% | 29*+9.6%134% | 29—229% | 31—385% | 29—170% | 26*—98.9% | |
| Operating income | −16—−18.3% | −7.4—−38.6% | −11—−75.3% | −8.0—−52.7% | 11*—27.1% | −19—−220% | −13—−83.9% | −20—−272% | −7.3*−2712%−34.2% | −17—−129% | −23—−285% | −12—−69.6% | 0.3*—1.1% | |
| Interest and finance income | 2.5−13.6%2.8% | 0.7+3.8%3.4% | 0.5−8.4%3.6% | 0.7−11.5%4.4% | 0.7*−30.2%1.7% | 0.6−25.3%7.4% | 0.6−39.9%3.8% | 0.8−17.4%10.0% | 0.9*+3.8%4.4% | 0.8—6.6% | 1.0—12.2% | 0.9—5.3% | 0.9*—3.4% | |
| Provision for credit losses | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Other non-operating income (expense) | −5.5—−6.3% | −1.3—−7.0% | −1.3—−8.7% | −1.3—−8.5% | −1.6*—−4.1% | −1.3—−15.0% | −1.0—−6.4% | −0.9—−12.5% | −4.0*—−18.5% | −4.9—−38.4% | −1.0—−12.3% | −0.5—−3.0% | −8.3*—−31.4% | |
| Income before tax | −19—−21.7% | −8.1—−42.2% | −12—−80.4% | −8.7—−56.8% | 9.6*—24.7% | −20—−228% | −13—−86.5% | −21—−274% | −10*—−48.3% | −21—−161% | −23—−285% | −11—−67.3% | −7.2*—−26.9% | |
| Income tax | 0.1+128%0.1% | 0.0+12.5%0.0% | 0.00.0%0.1% | 0.0+227%0.2% | 0.0*+500%0.0% | 0.0−20.0%0.1% | 0.00.0%0.1% | 0.0+10.0%0.1% | 0.0*−91.4%0.0% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0*—0.1% | |
| Net income attributable to shareholders | −19—−21.8% | −8.1—−42.2% | −12—−80.5% | −8.7—−57.1% | 9.6*—24.7% | −20—−228% | −13—−86.6% | −21—−274% | −10*—−48.4% | −21—−161% | −23—−285% | −12—−67.4% | −7.2*—−27.1% | |
| Earnings per share, basic | — | -0.08—— | -0.13—— | -0.10—— | — | -0.22—— | -0.16—— | -0.25—— | — | -0.29—— | -0.32—— | -0.16—— | — | |
| Earnings per share, diluted | — | -0.08—— | -0.13—— | -0.10—— | — | -0.22—— | -0.16—— | -0.25—— | — | -0.29—— | -0.32—— | -0.16—— | — | |
| Shares, weighted average (basic) | 107+18.8%— | 107+18.8%— | 91+6.6%— | 91+10.1%— | — | 90+25.3%— | 85+21.3%— | 82+18.0%— | — | 72—— | 70—— | 70—— | — | |
| Shares, weighted average (diluted) | 107+18.8%— | 107+18.8%— | 91+6.6%— | 91+10.1%— | — | 90+25.3%— | 85+21.3%— | 82+18.0%— | — | 72—— | 70—— | 70—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 29—20.3% | 29+15.2%20.3% | 27+1.5%22.6% | 37+99.6%28.3% | 51+164%34.4% | 25−32.3%20.5% | 27+43.9%19.4% | 18−68.4%14.2% | 19−70.4%12.9% | 37—25.3% | 19—14.1% | 58—38.8% | 65r65—47.7% | |
| Short-term investments | 43—30.1% | 43+30.3%30.1% | 28−29.9%23.1% | 29−31.2%22.1% | 27−49.4%18.5% | 33−36.8%26.9% | 40−27.5%28.6% | 42r41+50.9%32.2% | 54—36.4% | 53r53—35.6% | 55r55—41.4% | 28r27—18.4% | 0—0.0% | |
| Receivables | 16—10.9% | 16+60.8%10.9% | 12−29.3%9.7% | 8.0−30.7%6.2% | 11−43.4%7.2% | 9.7−41.2%7.9% | 16+33.1%11.9% | 12−18.4%9.0% | 19+88.2%12.7% | 17—11.2% | 12—9.4% | 14—9.5% | 10—7.3% | |
| Inventory | 2.1—1.5% | 2.1+8.3%1.5% | 1.6−17.6%1.3% | 2.0+12.3%1.5% | 1.8+1.0%1.2% | 1.9−7.9%1.6% | 1.9−12.9%1.4% | 1.8−27.0%1.4% | 1.8−33.0%1.2% | 2.1—1.4% | 2.2—1.7% | 2.4—1.6% | 2.7—2.0% | |
| Other current assets | 0.7—0.5% | 0.7+40.0%0.5% | 0.5+400%0.4% | 0.4−20.0%0.3% | 0.50.0%0.3% | 0.5+66.7%0.4% | 0.1−88.9%0.1% | 0.50.0%0.4% | 0.5−16.7%0.3% | 0.3—0.2% | 0.9—0.7% | 0.5—0.3% | 0.6—0.4% | |
| Current assets | 96—66.4% | 96+25.7%66.4% | 72−18.9%59.9% | 80+2.4%61.6% | 97−2.0%65.5% | 76−32.5%61.5% | 89−2.9%64.2% | 78−27.9%60.4% | 99+5.7%66.3% | 113—76.2% | 91—69.2% | 108—72.2% | 93—68.4% | |
| Property, plant and equipment | 13—9.2% | 13−4.9%9.2% | 12−20.5%9.9% | 13−20.3%9.7% | 13−8.3%8.8% | 14+5.6%11.3% | 15+7.3%10.8% | 16+7.7%12.3% | 14−8.3%9.5% | 13—9.0% | 14—10.6% | 15—9.8% | 15—11.3% | |
| Right-of-use (leased) assets | 28—19.2% | 28+4.3%19.2% | 29+5.0%23.8% | 30+5.6%22.9% | 31+6.3%20.6% | 27+146%21.4% | 27+135%19.7% | 28+126%21.7% | 29+118%19.3% | 11—7.3% | 12—8.8% | 12—8.3% | 13—9.6% | |
| Goodwill | 2.5—1.7% | 2.50.0%1.7% | 2.50.0%2.1% | 2.50.0%1.9% | 2.50.0%1.7% | 2.50.0%2.0% | 2.50.0%1.8% | 2.50.0%1.9% | 2.50.0%1.7% | 2.5—1.7% | 2.5—1.9% | 2.5—1.6% | 2.5—1.8% | |
| Total assets | 144—100% | 144+16.3%100% | 120−13.2%100% | 129+0.4%100% | 148−0.8%100% | 124−16.3%100% | 138+4.7%100% | 129−13.8%100% | 149+9.1%100% | 148—100% | 132—100% | 150—100% | 137—100% | |
| Accounts payable | 5.8—4.0% | 5.8+138%4.0% | 2.6+77.7%2.2% | 2.1−64.8%1.6% | 1.6−45.2%1.1% | 2.4−42.4%2.0% | 1.5−60.2%1.1% | 6.0+74.5%4.7% | 2.8−52.3%1.9% | 4.2—2.8% | 3.7—2.8% | 3.5—2.3% | 5.9—4.4% | |
| Debt due within a year | 12—8.2% | 12—8.2% | 7.1—5.9% | — | 0—0.0% | — | — | — | — | — | — | — | — | |
| Current liabilities | 34—23.6% | 34+84.5%23.6% | 24+54.3%19.6% | 15−29.0%11.5% | 25+7.1%17.1% | 18−47.4%14.9% | 15−50.1%11.0% | 21−28.1%16.2% | 24−34.0%15.9% | 35—23.7% | 31—23.1% | 29—19.4% | 36—26.2% | |
| Long-term debt | 29—20.4% | 29−25.8%20.4% | 34−14.1%28.2% | 40+38.7%31.3% | 40+38.7%27.1% | 40+38.8%32.0% | 39+38.8%28.5% | 29+3.9%22.6% | 29—19.4% | 29—19.3% | 28—21.5% | 28—18.8% | 0—0.0% | |
| Lease liabilities (non-current) | 28—19.4% | 28+8.7%19.4% | 28+6.8%23.7% | 29+6.3%22.5% | 30+7.1%20.4% | 26+182%20.8% | 27+161%19.2% | 27+144%21.3% | 28+130%18.9% | 9.1—6.2% | 10—7.7% | 11—7.5% | 12—9.0% | |
| Total liabilities | 93—64.5% | 93+8.9%64.5% | 87+5.4%72.5% | 86+8.7%66.6% | 97+18.5%65.8% | 85+14.2%68.9% | 83+17.1%59.8% | 79+12.8%61.5% | 82+64.3%55.1% | 75—50.5% | 71—53.5% | 70—47.0% | 50—36.6% | |
| Retained earnings | −636—−441% | −636—−441% | −627—−523% | −615—−476% | −607—−411% | −616—−497% | −597—−432% | −583—−453% | −563—−378% | −552—−373% | −532—−403% | −509—−340% | −498—−364% | |
| Shareholders' equity | 51—35.5% | 51+32.9%35.5% | 33−40.8%27.5% | 43−12.9%33.4% | 51−24.5%34.2% | 39−47.5%31.1% | 56−9.5%40.2% | 50−37.4%38.5% | 67−22.7%44.9% | 73—49.5% | 61—46.5% | 79—53.0% | 87—63.4% | |
| Total liabilities and equity | 144—100% | 144+16.3%100% | 120−13.2%100% | 129+0.4%100% | 148−0.8%100% | 124−16.3%100% | 138+4.7%100% | 129−13.8%100% | 149+9.1%100% | 148—100% | 132—100% | 150—100% | 137—100% | |
| Shares outstanding | 110—— | 110+21.3%— | 91+1.3%— | 91+9.7%— | 90+10.5%— | 90+10.9%— | 90+27.3%— | 83+17.4%— | 82+17.1%— | 81—— | 71—— | 71—— | 70—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 5.0−2.2%5.6% | 1.1*−16.2%5.9% | 1.2*−9.7%8.1% | 1.3+7.6%8.4% | 1.4*+12.2%3.5% | 1.4*+11.1%15.8% | 1.3*+6.0%8.7% | 1.2−4.6%15.8% | 1.2*−0.6%5.6% | 1.2*—9.5% | 1.3*—15.8% | 1.3—7.3% | 1.2*—4.6% | |
| Share-based compensation | 6.8−32.1%7.7% | 1.5−38.4%8.0% | 1.6−37.5%10.6% | 1.4−40.0%9.4% | 2.2*−12.9%5.7% | 2.5−7.2%29.2% | 2.5−45.9%16.5% | 2.4−25.0%31.5% | 2.5*+16.8%11.8% | 2.7—21.1% | 4.7—58.7% | 3.2—18.6% | 2.2*—8.1% | |
| Cash from operating activities | −10—−11.9% | −7.8*—−40.3% | −9.6*—−64.7% | −13—−86.2% | 20*—51.6% | −7.7*—−89.6% | −18*—−117% | −14—−183% | −16*—−76.7% | −13*—−101% | −12*—−153% | −7.8—−45.6% | −11*—−41.6% | |
| Capital expenditure | −1.7—−1.9% | −0.1*—−0.4% | −0.9*—−6.0% | −0.2—−1.2% | −0.5*—−1.3% | −0.2*—−2.1% | −2.5r−2.5*—−16.4% | −1.3r−1.3—−16.6% | −1.8*—−8.3% | −1.0*—−7.8% | −0.4*—−5.0% | −1.1—−6.6% | — | |
| Cash from investing activities | −11−173%−12.3% | −16*−344%−81.0% | 0.2*—1.2% | −1.1−109%−7.3% | 5.7*—14.7% | 6.4*+317%74.3% | −0.4*—−2.4% | 12—156% | −2.9*−359%−13.3% | 1.5*—11.9% | −27*—−339% | −29—−167% | 1.1*—4.2% | |
| Debt issued | — | 0*—0.0% | — | — | 0*—0.0% | 0*—0.0% | 9.9*—64.6% | 0−100%0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 30—173% | 0*—0.0% | |
| Shares issued | — | 27*—140% | — | — | −0.0*—−0.0% | 0*−100%0.0% | — | — | −0.0*—−0.0% | 31*—244% | 0*—0.0% | 0—0.0% | 0*—0.0% | |
| Cash from financing activities | 25−12.6%28.6% | 25*—130% | 0.1*−99.8%0.4% | −0.0−101%−0.1% | 0.2*−84.1%0.5% | −0.1*−100%−1.3% | 27*—175% | 1.1−96.3%14.4% | 1.1*—5.3% | 30*—236% | −0.2*—−2.5% | 29—172% | 0*—0.0% | |
| Change in cash | 3.9—4.4% | 1.6*—8.4% | −9.4*−211%−63.0% | −14—−93.6% | 26*—66.8% | −1.4*−108%−16.6% | 8.4*—55.1% | −0.9—−12.5% | −18*—−84.8% | 19*—147% | −39*—−494% | −7.1—−41.4% | −9.9*—−37.4% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Codexis, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Research and development revenue$44 M63%+97%
- Product revenue(total)$26 M37%-29%
Countries and regions
- Americas$44 M62%+105%
- 🇺🇸 USA$44 M62%+104%
- APAC$18 M25%-37%
- 🇨🇳 China$9 M13%-5.1%
- EMEA$9 M13%-10%
- 🇮🇳 India$6 M8.1%-22%
- 🇨🇭 Switzerland$4 M6.0%+24%
- 🇮🇪 Ireland$1 M1.0%-61%
- 🇸🇬 Singapore$0 M0.6%-94%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Codexis, Inc. operates: 6 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters3 offices | $44 M62% |
| 🇨🇳 China | $9 M13% | |
| 🇮🇳 India | $6 M8.1% | |
| 🇨🇭 Switzerland | $4 M6.0% | |
| 🇮🇪 Ireland | $1 M1.0% | |
| 🇸🇬 Singapore | $0 M0.6% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Codexis, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Stephen G. Dilly | $2.3 M | $921 K | $1.3 M | $35 |
| 2024Stephen G. Dilly | $3.5 M | $6.2 M | $1.3 M | $102 |
| 2023Stephen G. Dilly | $3.1 M | $1.2 M | $1.9 M | $65 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Codexis, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Restructuring 1 · Directors and officers 9 · Material agreement 1 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementAgreement endedNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| RestructuringDirectors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2019 | $50 M | Private placement after listing | $50 to $250 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Codexis, Inc.#
2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $120 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Research Associate II, Upstream Bioprocess DevelopmentFood Scientists and Technologists | 1 | $95 K |
| Scientist IIBioinformatics Scientists | 1 | $146 K |
Where: Redwood City, CA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 2 | 2 | $120 K | 3 |
| FY2023 | 6 | 6 | $117 K | 9 |
| FY2022 | 4 | 4 | $113 K | 5 |
| FY2021 | 2 | 2 | $124 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Codexis, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | · | · | 46 | · | 46 |
| 2023 | · | · | · | · | · | · | 59 | · | · | · | · | · | 59 |
| 2012 | · | · | · | · | · | · | · | 133 | 45 | · | · | · | 178 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 46 people (24% of workforce) | Restructuring planSEC 8-K | “In November 2025, Codexis eliminated 46 positions, or approximately 24% of its workforce.” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 25% of workforce | Restructuring planSEC 8-K | “As part of this enhanced strategic focus, the Company is streamlining operations, including discontinuing investment in certain development programs, primarily in Biotherapeutics, …” | Filing | |
| effective | 31 people | LayoffWARN notice | San Carlos, California | Notice list |
| effective | 28 people | LayoffWARN notice | Redwood City, California | Notice list |
| 45 people | Restructuring planSEC 8-K | “(the “Company”) committed to close its Singapore facility, which will include the termination of employment of approximately 45 employees at the Singapore facility.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Codexis, Inc. compares in Biotechnology
- Market cap$140 M · higher than 40% of 726
- Revenue$70 M · higher than 64% of 647
- Net margin-21.8% · higher than 60% of 408
- Revenue growth18.6% · higher than 60% of 438
- Price / sales1.6× · lower than 89% of 339
- Price / book2.8× · lower than 51% of 534
- FCF yield-17.0% · higher than 48% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Codexis, Inc.🇺🇸 | $140 M | — | -21.8% | +18.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikidata, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Codexis, Inc.? Verify and update this profile — free
Show Codexis, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.